Bone Growth Stimulation Market Size, Share, & Trends Analysis - Global - 2025-2031 - Includes: Ultrasound Market and Electrical Market
Description
Global Bone Growth Stimulation Market Report, 2025 Edition
Executive Summary
The global bone growth stimulation market was valued at $400 million in 2024. The market is expected to grow at a compound annual growth rate (CAGR) of 3.1 percent, reaching nearly $495 million by 2031.
This report covers electrical and ultrasound bone growth stimulators used for accelerating bone healing in trauma, spinal fusion, and nonunion procedures. It quantifies unit sales, average selling prices (ASPs), market values, growth rates, and company shares, and it analyzes growth drivers and limiters, recent mergers and acquisitions, product portfolios, and technology trends. Historical data extend to 2021, and forecasts continue through 2031.
Market Overview
Bone growth stimulation is an established segment of the orthopedic device industry, focused on enhancing and accelerating the body’s natural bone-healing process through electrical or ultrasound energy. These devices are used in patients with fractures, spinal fusion procedures, and nonunions where traditional healing is delayed or incomplete.
The market’s growth is supported by rising procedural volumes, clinical validation, and a strong evidence base demonstrating the efficacy of bone stimulation therapies. Both electrical and ultrasound stimulators are widely used to enhance osteogenesis by promoting cellular activity at the fracture or fusion site.
While clinical adoption remains steady, the market’s composition is shifting toward portable, patient-friendly devices that improve compliance and ease of use. Proper adherence to treatment protocols is a critical factor in achieving desired outcomes, and manufacturers are prioritizing user-centered design and digital connectivity to support patient engagement and real-time compliance monitoring.
Bone stimulators are prescribed for a growing range of conditions, including long-bone fractures, spinal fusion, nonunion fractures, and stress injuries in athletes and high-risk patients. The technology’s noninvasive nature and ability to complement surgical and biologic treatments position it as a valuable adjunct across both inpatient and outpatient care settings.
Market Drivers
Clinical Benefits
Bone growth stimulation technology is backed by decades of scientific research and clinical use. Both electrical and ultrasound-based systems have well-documented efficacy in enhancing healing rates and reducing time to union for indicated patients.
Electrical stimulators work by delivering pulsed electromagnetic fields (PEMF) or direct current across the fracture site, promoting osteoblast activity and bone formation. Ultrasound stimulators, such as low-intensity pulsed ultrasound (LIPUS), stimulate micro-mechanical signaling within bone cells to accelerate repair.
These mechanisms have proven reliable in controlled trials, with high success rates in fracture nonunion and spinal fusion cases. Continued positive outcomes and improved accessibility have helped maintain clinician confidence and reinforce reimbursement support in major healthcare systems.
Advancement of Biological Therapies
The development of biologic bone regeneration therapies, such as bone morphogenetic proteins (BMPs), complements rather than replaces bone growth stimulators. Biologics initiate the healing cascade but have a limited duration of activity, typically less than two weeks. Bone stimulators extend this process by providing sustained mechanical or electrical signaling over several months.
As a result, combined use of biologic grafts and bone stimulation is increasingly recommended for patients at risk of delayed union or poor bone quality. This synergistic relationship supports the ongoing relevance of stimulators in orthopedic and spinal applications, even as biologics continue to advance.
Reduced Invasiveness
A major growth driver for bone growth stimulators is their noninvasive or minimally invasive nature. External stimulators can be applied at home, avoiding additional surgical procedures and associated risks. This appeals to both patients and payers, as it reduces hospital costs and improves recovery times.
The simplicity of external systems allows them to be prescribed by orthopedic surgeons, sports medicine specialists, and physical therapists in both hospital and outpatient settings. This accessibility has expanded the addressable market and made stimulators a preferred option for patients who wish to avoid surgical interventions.
Ease of Patient Use and Compliance
Patient adherence is a critical factor in treatment success. The market is increasingly focused on simplified interfaces, lightweight designs, and smart monitoring features that track daily usage.
Manufacturers are investing in user-friendly technologies, including wireless connectivity and reminder notifications, to help patients follow prescribed regimens. By improving compliance, these features directly enhance therapeutic outcomes and drive stronger clinical adoption.
Future growth will be shaped by digital integration, where device usage data can be shared with physicians or insurance providers to verify compliance and optimize reimbursement. As usability improves, adoption is expected to rise among both clinicians and patients.
Market Limiters
Decreased Application in Low-Risk Patients
The primary limitation to market expansion is the restricted coverage criteria imposed by payers. Bone growth stimulators are high-value devices, with average prices ranging from $2,500 to $5,000 per unit depending on configuration and region.
While efficacy is well documented, insurers typically approve reimbursement only for high-risk or nonunion cases. Patients with low-risk fractures that are expected to heal naturally are excluded from coverage, which limits the eligible population.
These reimbursement criteria are unlikely to change significantly in the short term, as payers continue to focus on cost control and evidence-based utilization. This restriction keeps the market concentrated in specialized orthopedic applications rather than routine fracture management.
FDA Class III Regulation
Bone growth stimulators are regulated as Class III medical devices in the United States and similar high-risk categories internationally. This classification requires rigorous premarket approval (PMA) based on clinical data, which significantly increases the cost and time required to introduce new products.
The high regulatory barrier discourages smaller entrants and slows the rate of innovation. Self-administered devices, in particular, raise additional scrutiny regarding patient safety, electrical standards, and usability validation. As a result, only a handful of major companies dominate the global market, and new product approvals remain limited.
Pricing and Procurement Pressure
Like many orthopedic device segments, bone growth stimulation faces pricing pressure due to consolidated hospital purchasing and insurance-driven price controls. Group purchasing organizations (GPOs) and national tenders negotiate volume-based discounts that compress margins, particularly in developed markets.
Although clinical benefits justify premium pricing, the trend toward value-based care models is pushing suppliers to demonstrate measurable outcomes and cost-effectiveness. This is expected to sustain pricing pressure through the forecast period, moderating value growth despite stable unit demand.
Market Coverage and Data Scope
Time Frame: Base year 2024, forecasts 2025–2031, historical data 2021–2023.
Care Settings: Hospitals, orthopedic clinics, spine centers, and outpatient rehabilitation facilities.
Methodology: Market revenue is modeled as units multiplied by ASP, validated with procedure data, hospital procurement reports, and manufacturer-disclosed revenue.
Market Segmentation Summary
Bone Growth Stimulation Market – Further Segmented Into:
Electrical Bone Growth Stimulators
Ultrasound Bone Growth Stimulators
Quantitative Coverage: Market size, company shares, forecasts, growth rates, units sold, and average selling prices.
Qualitative Coverage: Market trends, limiters, competitive analysis and SWOT for leading competitors, mergers and acquisitions, product portfolios, regulatory developments, and disease overviews.
Data Sources: Primary interviews with industry experts, government physician and regulatory data, hospital procurement inputs, import and export statistics, and iData Research’s proprietary database.
Competitive Analysis
Bioventus
Bioventus held the leading share of the global bone growth stimulation market in 2024. The company’s flagship Exogen® Bone Healing System dominates the ultrasound segment, representing a majority of total market value. Bioventus maintains strong commercial operations in North America, Western Europe, and several emerging markets. Its product’s noninvasive design, proven clinical efficacy, and robust reimbursement coverage continue to support its leadership position.
ZimVie (formerly Zimmer Biomet Dental/Highridge Medical)
ZimVie ranked second globally, driven by its OsteoGen® internal bone growth stimulation system. This system remains one of the few internal options available on the market and is often used in spinal fusion and complex trauma cases. ZimVie’s geographic breadth and clinical credibility provide a stable competitive advantage, and the company is expected to maintain its strong position over the forecast period.
Orthofix
Orthofix held the third-largest share with its PhysioStim™ external bone growth stimulator, a widely recognized device in the electrical stimulation category. Orthofix continues to invest in R&D and patient-centric improvements to enhance compliance and portability. The company is expected to gain modest market share as clinical adoption expands and as newer designs focus on comfort and ease of daily use.
Other market participants include smaller specialty manufacturers focused on regional markets and niche applications. However, the global competitive landscape remains concentrated, with the top three companies accounting for the majority of total revenue.
Technology and Practice Trends
Portable external devices continue to replace bulkier, clinic-based systems. Wearable form factors increase patient comfort and compliance.
Bluetooth-enabled stimulators and mobile apps allow real-time monitoring of daily usage, promoting adherence and linking compliance data to clinical outcomes.
Combined biological and electrical therapy approaches are being studied to improve long-term union rates.
Miniaturization of components is allowing extended wear times and lower power requirements, reducing maintenance needs.
Educational outreach programs by manufacturers aim to increase awareness among orthopedic surgeons, sports medicine practitioners, and rehabilitation specialists.
Geography
This edition provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Why This Report
Identify which technology segments—electrical or ultrasound—are driving market growth and in which regions.
Benchmark company shares and understand how clinical positioning and ease-of-use design are shaping competition.
Quantify how regulatory barriers and reimbursement policies affect new product introduction.
Explore how biologic therapies and digital monitoring are influencing the next wave of product innovation.
Assess pricing, tendering, and procurement trends that impact manufacturer margins.
Plan commercial strategy using country-level forecasts and validated ASP and unit models.
The Global Bone Growth Stimulation Market Report from iData Research provides the most comprehensive quantitative and qualitative analysis of this growing orthopedic market.
It helps manufacturers, investors, and commercial teams understand technology adoption patterns, pricing dynamics, and competitive positioning at both global and regional levels.
About iData Research
iData Research is a premium market intelligence firm headquartered in Canada with offices across North America and Europe.
Over the last 20 years, the company has specialized in device-level sizing, procedure models, pricing trends, and competitive share across MedTech.
Since 2005, iData has supported global OEMs, mid-market innovators, and investors with triangulated data based on units and ASPs, with country-level forecasts and analyst access across Europe, North America, Latin America, the Middle East, Africa, and APAC.
Reports are available with flexible licensing to fit commercial, strategy, and investment workflows
Executive Summary
The global bone growth stimulation market was valued at $400 million in 2024. The market is expected to grow at a compound annual growth rate (CAGR) of 3.1 percent, reaching nearly $495 million by 2031.
This report covers electrical and ultrasound bone growth stimulators used for accelerating bone healing in trauma, spinal fusion, and nonunion procedures. It quantifies unit sales, average selling prices (ASPs), market values, growth rates, and company shares, and it analyzes growth drivers and limiters, recent mergers and acquisitions, product portfolios, and technology trends. Historical data extend to 2021, and forecasts continue through 2031.
Market Overview
Bone growth stimulation is an established segment of the orthopedic device industry, focused on enhancing and accelerating the body’s natural bone-healing process through electrical or ultrasound energy. These devices are used in patients with fractures, spinal fusion procedures, and nonunions where traditional healing is delayed or incomplete.
The market’s growth is supported by rising procedural volumes, clinical validation, and a strong evidence base demonstrating the efficacy of bone stimulation therapies. Both electrical and ultrasound stimulators are widely used to enhance osteogenesis by promoting cellular activity at the fracture or fusion site.
While clinical adoption remains steady, the market’s composition is shifting toward portable, patient-friendly devices that improve compliance and ease of use. Proper adherence to treatment protocols is a critical factor in achieving desired outcomes, and manufacturers are prioritizing user-centered design and digital connectivity to support patient engagement and real-time compliance monitoring.
Bone stimulators are prescribed for a growing range of conditions, including long-bone fractures, spinal fusion, nonunion fractures, and stress injuries in athletes and high-risk patients. The technology’s noninvasive nature and ability to complement surgical and biologic treatments position it as a valuable adjunct across both inpatient and outpatient care settings.
Market Drivers
Clinical Benefits
Bone growth stimulation technology is backed by decades of scientific research and clinical use. Both electrical and ultrasound-based systems have well-documented efficacy in enhancing healing rates and reducing time to union for indicated patients.
Electrical stimulators work by delivering pulsed electromagnetic fields (PEMF) or direct current across the fracture site, promoting osteoblast activity and bone formation. Ultrasound stimulators, such as low-intensity pulsed ultrasound (LIPUS), stimulate micro-mechanical signaling within bone cells to accelerate repair.
These mechanisms have proven reliable in controlled trials, with high success rates in fracture nonunion and spinal fusion cases. Continued positive outcomes and improved accessibility have helped maintain clinician confidence and reinforce reimbursement support in major healthcare systems.
Advancement of Biological Therapies
The development of biologic bone regeneration therapies, such as bone morphogenetic proteins (BMPs), complements rather than replaces bone growth stimulators. Biologics initiate the healing cascade but have a limited duration of activity, typically less than two weeks. Bone stimulators extend this process by providing sustained mechanical or electrical signaling over several months.
As a result, combined use of biologic grafts and bone stimulation is increasingly recommended for patients at risk of delayed union or poor bone quality. This synergistic relationship supports the ongoing relevance of stimulators in orthopedic and spinal applications, even as biologics continue to advance.
Reduced Invasiveness
A major growth driver for bone growth stimulators is their noninvasive or minimally invasive nature. External stimulators can be applied at home, avoiding additional surgical procedures and associated risks. This appeals to both patients and payers, as it reduces hospital costs and improves recovery times.
The simplicity of external systems allows them to be prescribed by orthopedic surgeons, sports medicine specialists, and physical therapists in both hospital and outpatient settings. This accessibility has expanded the addressable market and made stimulators a preferred option for patients who wish to avoid surgical interventions.
Ease of Patient Use and Compliance
Patient adherence is a critical factor in treatment success. The market is increasingly focused on simplified interfaces, lightweight designs, and smart monitoring features that track daily usage.
Manufacturers are investing in user-friendly technologies, including wireless connectivity and reminder notifications, to help patients follow prescribed regimens. By improving compliance, these features directly enhance therapeutic outcomes and drive stronger clinical adoption.
Future growth will be shaped by digital integration, where device usage data can be shared with physicians or insurance providers to verify compliance and optimize reimbursement. As usability improves, adoption is expected to rise among both clinicians and patients.
Market Limiters
Decreased Application in Low-Risk Patients
The primary limitation to market expansion is the restricted coverage criteria imposed by payers. Bone growth stimulators are high-value devices, with average prices ranging from $2,500 to $5,000 per unit depending on configuration and region.
While efficacy is well documented, insurers typically approve reimbursement only for high-risk or nonunion cases. Patients with low-risk fractures that are expected to heal naturally are excluded from coverage, which limits the eligible population.
These reimbursement criteria are unlikely to change significantly in the short term, as payers continue to focus on cost control and evidence-based utilization. This restriction keeps the market concentrated in specialized orthopedic applications rather than routine fracture management.
FDA Class III Regulation
Bone growth stimulators are regulated as Class III medical devices in the United States and similar high-risk categories internationally. This classification requires rigorous premarket approval (PMA) based on clinical data, which significantly increases the cost and time required to introduce new products.
The high regulatory barrier discourages smaller entrants and slows the rate of innovation. Self-administered devices, in particular, raise additional scrutiny regarding patient safety, electrical standards, and usability validation. As a result, only a handful of major companies dominate the global market, and new product approvals remain limited.
Pricing and Procurement Pressure
Like many orthopedic device segments, bone growth stimulation faces pricing pressure due to consolidated hospital purchasing and insurance-driven price controls. Group purchasing organizations (GPOs) and national tenders negotiate volume-based discounts that compress margins, particularly in developed markets.
Although clinical benefits justify premium pricing, the trend toward value-based care models is pushing suppliers to demonstrate measurable outcomes and cost-effectiveness. This is expected to sustain pricing pressure through the forecast period, moderating value growth despite stable unit demand.
Market Coverage and Data Scope
Time Frame: Base year 2024, forecasts 2025–2031, historical data 2021–2023.
Care Settings: Hospitals, orthopedic clinics, spine centers, and outpatient rehabilitation facilities.
Methodology: Market revenue is modeled as units multiplied by ASP, validated with procedure data, hospital procurement reports, and manufacturer-disclosed revenue.
Market Segmentation Summary
Bone Growth Stimulation Market – Further Segmented Into:
Electrical Bone Growth Stimulators
Ultrasound Bone Growth Stimulators
Quantitative Coverage: Market size, company shares, forecasts, growth rates, units sold, and average selling prices.
Qualitative Coverage: Market trends, limiters, competitive analysis and SWOT for leading competitors, mergers and acquisitions, product portfolios, regulatory developments, and disease overviews.
Data Sources: Primary interviews with industry experts, government physician and regulatory data, hospital procurement inputs, import and export statistics, and iData Research’s proprietary database.
Competitive Analysis
Bioventus
Bioventus held the leading share of the global bone growth stimulation market in 2024. The company’s flagship Exogen® Bone Healing System dominates the ultrasound segment, representing a majority of total market value. Bioventus maintains strong commercial operations in North America, Western Europe, and several emerging markets. Its product’s noninvasive design, proven clinical efficacy, and robust reimbursement coverage continue to support its leadership position.
ZimVie (formerly Zimmer Biomet Dental/Highridge Medical)
ZimVie ranked second globally, driven by its OsteoGen® internal bone growth stimulation system. This system remains one of the few internal options available on the market and is often used in spinal fusion and complex trauma cases. ZimVie’s geographic breadth and clinical credibility provide a stable competitive advantage, and the company is expected to maintain its strong position over the forecast period.
Orthofix
Orthofix held the third-largest share with its PhysioStim™ external bone growth stimulator, a widely recognized device in the electrical stimulation category. Orthofix continues to invest in R&D and patient-centric improvements to enhance compliance and portability. The company is expected to gain modest market share as clinical adoption expands and as newer designs focus on comfort and ease of daily use.
Other market participants include smaller specialty manufacturers focused on regional markets and niche applications. However, the global competitive landscape remains concentrated, with the top three companies accounting for the majority of total revenue.
Technology and Practice Trends
Portable external devices continue to replace bulkier, clinic-based systems. Wearable form factors increase patient comfort and compliance.
Bluetooth-enabled stimulators and mobile apps allow real-time monitoring of daily usage, promoting adherence and linking compliance data to clinical outcomes.
Combined biological and electrical therapy approaches are being studied to improve long-term union rates.
Miniaturization of components is allowing extended wear times and lower power requirements, reducing maintenance needs.
Educational outreach programs by manufacturers aim to increase awareness among orthopedic surgeons, sports medicine practitioners, and rehabilitation specialists.
Geography
This edition provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Why This Report
Identify which technology segments—electrical or ultrasound—are driving market growth and in which regions.
Benchmark company shares and understand how clinical positioning and ease-of-use design are shaping competition.
Quantify how regulatory barriers and reimbursement policies affect new product introduction.
Explore how biologic therapies and digital monitoring are influencing the next wave of product innovation.
Assess pricing, tendering, and procurement trends that impact manufacturer margins.
Plan commercial strategy using country-level forecasts and validated ASP and unit models.
The Global Bone Growth Stimulation Market Report from iData Research provides the most comprehensive quantitative and qualitative analysis of this growing orthopedic market.
It helps manufacturers, investors, and commercial teams understand technology adoption patterns, pricing dynamics, and competitive positioning at both global and regional levels.
About iData Research
iData Research is a premium market intelligence firm headquartered in Canada with offices across North America and Europe.
Over the last 20 years, the company has specialized in device-level sizing, procedure models, pricing trends, and competitive share across MedTech.
Since 2005, iData has supported global OEMs, mid-market innovators, and investors with triangulated data based on units and ASPs, with country-level forecasts and analyst access across Europe, North America, Latin America, the Middle East, Africa, and APAC.
Reports are available with flexible licensing to fit commercial, strategy, and investment workflows
Table of Contents
49 Pages
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
